Version 4.4. Institutional Outcomes Report 2014Q3. National Outcomes Report Aggregation Date: Jan 12, :59:59 PM

Similar documents
Data Requirements. Accreditation for Cardiovascular Excellence Quality in Invasive Cardiovascular Care

Cardiothoracic Department October 9, Deborah Winters, RN BSN Clinical Excellence

NCDR CathPCI Registry v4.4 Diagnostic Catheterization and Percutaneous Coronary Intervention Registry

Ischemic Heart Disease Interventional Treatment

Ischemic Heart Disease Interventional Treatment

2/26/2013. NCDR.13 Case Scenario Presentation Cath PCI Registry. Disclosures. Objectives. Dashboard Implications of Some Major Metrics

Institutional Outcomes Report 2012Q2 Sample Hospital

New Jersey Cardiac Catheterization Data Registry, Version 2.0 (Please report data only for patients 16 years or older.)

Coronary Catheterization and Percutaneous Coronary Intervention in China 10-Year Results From the China PEACE-Retrospective CathPCI Study

Timing of Surgery After Percutaneous Coronary Intervention

Data Elements and Definitions with Case Studies. Interpreting Your Outcomes Reports. Kim Hustler, Clinical Quality Consultant, NCDR

CathPCI Registry Poster Abstract

PCIs on Intermediate Lesions NCDR Cath-PCI Registry

STEMI, Non-STEMI, Chest Pain?

THE NATIONAL QUALITY FORUM

Blue Distinction Centers for Cardiac Care 2018 Provider Survey

Practice-Level Executive Summary Report

Consensus Core Set: Cardiovascular Measures Version 1.0

STEMI update. Vijay Krishnamoorthy M.D. Interventional Cardiology

4. Which survey program does your facility use to get your program designated by the state?

National Cardiovascular Data Registry

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

Bivalirudin Clinical Trials Update Evidence and Future Perspectives

Decrease cost of inpatient stay Decrease bed diversions Improve bed utilization (Interqual Criteria) Patient Satisfaction Reduce patient costs

Clinical Lessons from BMC2-PCI

Belinda Green, Cardiologist, SDHB, 2016

CLINICIAN INTERVIEW RECOGNIZING ACS AND STRATIFYING RISK IN PRIMARY CARE. An interview with A. Michael Lincoff, MD, and Eric R. Bates, MD, FACC, FAHA

DECLARATION OF CONFLICT OF INTEREST

Quinn Capers, IV, MD

The Evolving ACC-NCDR Programs: What you need to know for your practice

Why and How Should We Switch Clopidogrel to Prasugrel?

CPORT E Trial. Atlantic C PORT

2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Efficiency

Imaging ischemic heart disease: role of SPECT and PET. Focus on Patients with Known CAD

Cardiac evaluation for the noncardiac. Nathaen Weitzel MD University of Colorado Denver Dept of Anesthesiology

Fractional Flow Reserve: Review of the latest data

Know the Quality of our Care at Every Step. Kansas City ACS Summit BI-State Cardiovascular Education Consortium

Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial

Treatment Options for Angina

DIFFERENTIATING THE PATIENT WITH UNDIFFERENTIATED CHEST PAIN

Transfer in D2B. Scott D Friedman, MD FACC Medical Director, Cardiology Services Shore Health System of Maryland. The Problem

Is the role of bivalirudin established?

UNIVERSITY OF OKLAHOMA INTERVENTIONAL CARDIOLOGY FELLOWSHIP CURRICULUM

STEMI AND MULTIVESSEL CORONARY DISEASE

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor

Cardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008.

Simon A. Mahler MD, MS, FACEP Associate Professor Department of Emergency Medicine Wake Forest School of Medicine

2013, American Heart Association

6/1/18 LEARNING OBJECTIVES PATIENT POPULATION PRESENTATIONS

2/26/2013. Appropriateness Use Criteria (Drilldown) Disclosures. Tony Hermann has nothing to disclose. Mark Hutcheson has nothing to disclose

Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines)

Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά

(For items 1-12, each question specifies mark one or mark all that apply.)

FFR in Multivessel Disease

2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non ST-Elevation Myocardial Infarction

Supplementary Online Content

Non ST Elevation-ACS. Michael W. Cammarata, MD

Percutaneous Coronary Interventions Without On-site Cardiac Surgery

Declaration of conflict of interest NONE

Patient Navigator Program: Focus MI Diplomat Hospital Metrics

Coronary Artery Disease: Revascularization (Teacher s Guide)

Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD

8/28/2018. Pre-op Evaluation for non cardiac surgery. A quick review from 2007!! Disclosures. John Steuter, MD. None

Continuing Medical Education Post-Test

Dashboard and Outcomes Report with Case Studies

Myocardial Infarction In Dr.Yahya Kiwan

Jun-Won Lee, Sang Wook Park, Jung-Woo Son, Young Jin Youn, Min-Soo Ahn, Sung Gyun Ahn, Jang-Young Kim, Byung-Soo Yoo, Junghan Yoon, Seung-Hwan Lee

Clopidogrel Date: 15 July 2008

The PAIN Pathway for the Management of Acute Coronary Syndrome

Disclosures. Inpatient Management of Non-ST Elevation Acute Coronary Syndromes. Edward McNulty MD, FACC. None

Target vessel only revascularization versus complet revascularization in non culprit lesions in acute myocardial infarction treated by primary PCI

From Recovery to Transplant: One Patient's Journey

Σεμινάριο Ομάδων Εργασίας Fractional Flow Reserve (FFR) Σε ποιούς ασθενείς; ΔΗΜΗΤΡΗΣ ΑΥΖΩΤΗΣ Επιστ. υπεύθυνος Αιμοδυναμικού Τμήματος, Βιοκλινική

Coronary Angiogram Database of South Australia

Clinical case in perspective. Cases from Poland

Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015

Acute Coronary Syndromes

A Multicenter Randomized Trial of Immediate Versus Delayed Invasive Strategy in Patients with Non-ST Elevation ACS

Optimal Duration and Dose of Antiplatelet Therapy after PCI

HIP ATTACK Trial: Can we improve outcomes after a hip fracture with accelerated surgery? PJ Devereaux, MD, PhD

Case Study 50 YEAR OLD MALE WITH UNSTABLE ANGINA

Acute Coronary Syndrome. Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine

Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines)

Benefit of Performing PCI Based on FFR

A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS

Quality Payment Program: Cardiology Specialty Measure Set

Measurement Name Beta-Blocker Therapy Prior Myocardial Infarction (MI)

Supplementary Online Content

Management of Cardiogenic shock. Prof. Christian JM Vrints

Indications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014

Acute Coronary Syndrome (ACS) Initial Evaluation and Management

KCS Congress: Impact through collaboration

DESCRIPTION: Percentage of patients aged 18 years and older undergoing isolated CABG surgery who received an IMA graft

EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017

Program Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name

Hospital-Acquired Anemia: Epidemiology, Prevention and Management in Patients with Acute Coronary Syndromes

JAWDA Quarterly Waiting Time Guidelines for (Specialized and General Hospitals)

Downloaded from:

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes

Transcription:

Version 4.4 Institutional Outcomes Report 2014Q3 National Outcomes Report 999997 Aggregation Date: Jan 12, 2015 11:59:59 PM Publish Date: Jan 29, 2015 If User desires to publish or otherwise distribute or use, in whole or in part, any aggregate data or reports provided by ACCF, or produced in connection with or derived from NCDR, with the exception of strictly internal use within User's organization, User must first obtain the prior express written consent of ACCF. To the extent User is permitted to publish aggregate data, such aggregate data and any related information published in connection with it must be reviewed and approved by ACCF prior to publication. National Cardiovascular Data Registry 800-257-4737 www.ncdr.com ncdr@acc.org NCDR

Section I: PCI Performance Measures Endorsed by the National Quality Forum and appropriate for public reporting PCI Performance Measures 1 PCI in-hospital risk adjusted mortality (all patients) 1.80 0.99 Your hospital s PCI in-hospital risk adjusted mortality rate for all patients adjusted using the NCDR risk adjustment model. [Detail Line:2036] 37 PCI in-hospital risk adjusted rate of bleeding events (all patients) 4.18 1.74 Your hospital s risk adjusted rate of bleeding events for patients with PCI procedures using the NCDR PCI bleeding risk adjustment model. [Detail Line:1823] 38 Composite: Discharge Medications in Eligible PCI Patients 94.5% 99.1% Patients with a PCI procedure who receive prescriptions for all medications (aspirin, P2Y12 inhibitor, and statin) for which they are eligible for at discharge. [Detail Line:2007] Note Performance measures in the have been endorsed by the National Quality Forum. Such performance measures meeting the requirement for approval are intended not only for clinical quality improvement, but also may be considered for purposes of public reporting. The Registry Metrics on the subsequent pages of this report are those measures that have been developed to support self assessment and quality improvement at the provider, hospital, and/or health care system level. While these metrics have not been formally developed by the American College of Cardiology/American Heart Association Task Force for Performance Measures Task Force, they may be identified as evolving measures worthy of consideration for further development into performance measures. NCDR

Section II: Quality Metrics to support self assessment and quality improvement at the provider, hospital, and/or health care system level. PCI Process Metrics 2 Proportion of elective PCIs with prior positive stress or imaging study 67.51% 90.02% Proportion of elective PCI procedures (excluding patients with ACS) with an antecedent stress or imaging study with a positive result (suggestive of ischemia) or with a fractional flow reserve value of <=0.8 during the PCI procedure [Detail Line:1513] 3 Median time to immediate PCI for STEMI patients (in minutes) 60 48 Your hospital s median time from hospital arrival to immediate PCI for STEMI patients in minutes. Exclusions: Patients transferred in from another acute care facility; Reasons for delay does not equal none. [Detail Line:1502] 4 Proportion of STEMI patients receiving immediate PCI w/in 90' 94.93% 100.00% Proportion of STEMI patients with a time from your hospital arrival (or subsequent ECG if ST elevation first noted on subsequent ECG) to immediate PCI <=90'. Exclusions: Patients transferred in from another acute care facility; Reasons for delay does not equal none. [Detail Line:1503] 5 Median time from ED arrival at STEMI transferring facility to ED arrival at STEMI receiving facility among transferred patients. 74 50 Your hospital s median time from arrival at transferring facility to ED arrival at STEMI receiving facility among transferred patients. [Detail Line:1505] 6 Median time from ED arrival at STEMI transferring facility to immediate PCI at STEMI receiving facility among transferred patients (in minutes) 108 80 Your hospital s median time from arrival at referring facility to immediate PCI at STEMI receiving facility among transferred patients. Exclusions: Reasons for delay does not equal none. [Detail Line:1506] 7 Median fluoro time (in minutes) 10 7 Inclusion criteria: PCI of one vessel/lesion. Exclusion criteria: Prior CABG, or other procedure during the same lab visit; PCI of >1 vessel/lesion. [Detail Line:1633] 8 Proportion of patients with aspirin prescribed at discharge 98.8% 100.0% Proportion of patients (without a documented contraindication) with aspirin prescribed at discharge. [Detail Line:1997] 9 Proportion of patients with a P2Y12 inhibitor prescribed at discharge 99.5% 100.0% Proportion of patients (without a documented contraindication) with a stent implanted that had a thienopyridine/p2y12 inhibitor prescribed at discharge. [Detail Line:2006] NCDR

Section II: Quality Metrics to support self assessment and quality improvement at the provider, hospital, and/or health care system level. 10 Statins prescribed at discharge 96.0% 99.5% Proportion of patients (without a documented contraindication) prescribed a statin at discharge. [Detail Line:2002] PCI Outcome Metrics 12 Emergency CABG post PCI 0.0% 0.0% Proportion of PCI patients with post procedure Emergency CABG. [Detail Line:1980] 13 Proportion of PCI procedures with a post procedure MI (among hospitals routinely collecting post-pci biomarkers)** 1.51% 0.00% Your hospital s proportion of biomarker positive, post procedure myocardial infarction. Inclusions: Submissions with >= 90% of pts with biomarkers coded; LOS>=1; Elective patients [Detail Line:1803] 14 Proportion of PCI procedures with post procedure MI (among hospitals who do not routinely collect post-pci biomarkers)** 0.00% 0.00% Your hospital s proportion of biomarker positive, post procedure myocardial infarction. Inclusions: Submissions with < 90% of pts with biomarkers coded; LOS>=1; Elective patients [Detail Line:1804] 16 Proportion of PCI procedures with post procedure stroke 0.07% 0.00% Your hospital s proportion of patients with stroke post procedure. [Detail Line:1811] 17 Composite: Proportion of PCI patients with death, emergency CABG, stroke or repeat target vessel revascularization. 2.59% 0.85% Your hospital s proportion of patients with death, emergency CABG, stroke or repeat target vessel revascularization post procedure up to hospital discharge. Excludes patients with stroke and an elective, urgent or salvage CABG during same admission. [Detail Line:1801] 18 PCI in-hospital risk adjusted mortality (patients with STEMI) 6.50 3.44 Your hospital s PCI in-hospital risk adjusted mortality rate for patients with STEMI adjusted using the NCDR risk adjustment model. [Detail Line:2045] 19 PCI in-hospital risk adjusted mortality (STEMI patients excluded) 0.87 0.41 Your hospital s PCI in-hospital risk adjusted mortality rate for patients with other diagnoses (not STEMI) using the NCDR risk adjustment model. [Detail Line:2054] NCDR

Section II: Quality Metrics to support self assessment and quality improvement at the provider, hospital, and/or health care system level. 25 Proportion of PCI procedures with transfusion of whole blood or RBCs 1.18% 0.00% Proportion of patients who received a transfusion of whole blood or red blood cells after a PCI procedure. Inclusion: Patients with a pre-procedure hemoglobin >8 g/dl and patients with no CABG, and no other major surgery during the same admission. [Detail Line:1853] 39 PCI in-hospital risk adjusted acute kidney injury (all patients) 6.13 2.85 Your hospital s PCI in-hospital risk adjusted AKI rate for all patients adjusted using the NCDR risk adjustment model. [Detail Line:1960] Diagnostic Cath Process Metrics 20 Incidence of non-obstructive CAD (elective patients only) 42.79% 29.15% Patients with an elective diagnostic cath and coronary angiography with all native coronary territories <50% Exclusions: Patients with prior CABG, cardiac transplant evaluation; pre-op evaluation for non-cardiac surgery and diagnostic cath treatment recommendation of other cardiac therapy without CABG or PCI. [Detail Line:1252] Diagnostic Cath Outcomes Metrics 21 Proportion of Diagnostic Catheterization procedures with vascular access site injury requiring treatment or major bleeding* 0.09% 0.00% Your hospital s proportion of patients with major access site related injury requiring treatment or major bleeding. [Detail Line:1301] Utilization Metrics 22 Median post-procedure length of stay (in days) for PCI patients with STEMI 2.5 1.6 Your hospital s median post-procedure length of stay (in days) for PCI patients with STEMI. [Detail Line:2110] Data Quality Metrics 24 Proportion of PCI procedures with creatinine assessed pre and post PCI 90.05% 97.64% Proportion of PCI patients with creatinine assessed pre and post procedure. Exclusions: LOS<1 day and death in lab. [Detail Line:1951] NCDR

Section II: Quality Metrics to support self assessment and quality improvement at the provider, hospital, and/or health care system level. Test Metrics 26 Test Data Quality Metric: Proportion of PCI procedures with biomarkers assessed post-pci for elective inpatients 25.7% 91.2% Proportion of elective procedures with biomarkers assessed post PCI. Exclusions: LOS<1 day, or hospital status=outpatient, or death in lab. [Detail Line:1949] NCDR

(999997) compared to Rolling Four Quarters (R4Q) for US Hospitals ending Section III: PCI Appropriate Use Criteria (AUC) Metrics These data are based upon the 2012 Appropriateness Criteria for Coronary Revascularization Focused Update (J Am Coll Cardiol 2012 59: 857-881) document developed by the ACC, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Heart Association, and other national societies. These metrics are designed to provide sites feedback on the appropriateness of percutaneous coronary intervention procedures at the hospital level.pci AUC metrics are not appropriate for public/external reporting PCI Appropriate Use Criteria (AUC) Metrics 30 Proportion of PCI procedures not classifiable for AUC reporting 3.80% 0.31% Proportion of PCI procedures that were not classifiable/evaluated for PCI AUC reporting due to incomplete or missing data. [Detail Line:1589] 31 Patients WITH Acute Coronary Syndrome: Proportion of evaluated PCI procedures that were appropriate 98.91% 100.00% Proportion of PCI procedures that were evaluated as Appropriate, among patients with ACS, meaning coronary revascularization is generally acceptable and is a reasonable approach for the indication and is likely to improve the patients health outcomes or survival. [Detail Line:1581] 32 Patients WITH Acute Coronary Syndrome: Proportion of evaluated PCI procedures that were of uncertain appropriateness 0.72% 3.83% Proportion of PCI procedures that were evaluated as Uncertain, among patients with ACS, meaning coronary revascularization may be acceptable and may be a reasonable approach for the indication. However, some degree of uncertainty exists, implying that more research and/or patient information is needed to determine whether the procedure would improve patients health outcomes or survival. [Detail Line:1582] 33 Patients WITH Acute Coronary Syndrome: Proportion of evaluated PCI procedures that were inappropriate 0.00% 0.00% Proportion of PCI procedures that were evaluated as Inappropriate, among patients with ACS, meaning coronary revascularization is not generally acceptable and is not a reasonable approach for the indication and is unlikely to improve the patients health outcomes or survival. [Detail Line:1583] 34 Patients WITHOUT Acute Coronary Syndrome: Proportion of evaluated PCI procedures that were appropriate 50.17% 76.59% Proportion of PCI procedures that were evaluated as Appropriate, among patients without ACS, meaning coronary revascularization is generally acceptable and is a reasonable approach for the indication and is likely to improve the patients health outcomes or survival. [Detail Line:1585] 35 Patients WITHOUT Acute Coronary Syndrome: Proportion of evaluated PCI procedures that were of uncertain appropriateness 32.79% 52.81% Proportion of PCI procedures that were evaluated as Uncertain, among patients without ACS, meaning coronary revascularization may be acceptable and may be a reasonable approach for the indication. However, some degree of uncertainty exists, implying that more research and/or patient information is needed to determine whether the procedure would improve patients health outcomes or survival. [Detail Line:1586] NCDR

(999997) compared to Rolling Four Quarters (R4Q) for US Hospitals ending Section III: PCI Appropriate Use Criteria (AUC) Metrics These data are based upon the 2012 Appropriateness Criteria for Coronary Revascularization Focused Update (J Am Coll Cardiol 2012 59: 857-881) document developed by the ACC, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Heart Association, and other national societies. These metrics are designed to provide sites feedback on the appropriateness of percutaneous coronary intervention procedures at the hospital level.pci AUC metrics are not appropriate for public/external reporting 36 Patients WITHOUT Acute Coronary Syndrome: Proportion of evaluated PCI procedures that were inappropriate 13.22% 0.00% Proportion of PCI procedures that were evaluated as Inappropriate, among patients without ACS, meaning coronary revascularization is not generally acceptable and is not a reasonable approach for the indication and is unlikely to improve the patients health outcomes or survival. [Detail Line:1587] Executive Summary Footnotes *Vascular access site injury requiring treatment or major bleeding is defined as: 1.Bleeding at access site, hematoma at access site, or retroperitoneal bleed that occur within 72 hours of the procedure. To qualify, the event must be associated with a hemoglobin drop of >= 3 g/dl; transfusion of whole or packed red blood cells, or a procedural intervention/surgery at the bleeding site to reverse/stop or correct the bleeding. This excludes GI, GU and Other bleeds. 2.Major access site related injury requiring treatment includes access site occlusion, peripheral embolization, dissection, pseudoaneurysm, AV fistula requiring treatment anytime from the procedure until discharge. **Your rate of post procedure MI cannot be reported if you only collected cardiac biomarkers on <90% of your patients who were in the hospital >=1 day. NCDR

Section IV: PCI Process Comparison Metrics Anticoagulant Use: Any Low molecular weight/unfractionated heparin, direct thrombin inhibitors, GP llb/llla inhibitor(pts with acute coronary syndrome). [Detail Line:1600,1601,1606] 70% 60% 50% 40% 30% 20% 10% 0% LMWH/Unfractionated DTI GP llb/llla My Hospital Comparison Group US Hospitals Intermediate stenosis lesions(40-70%): Further invasive evaluation performed (IVUS or FFR). [Detail Line:1732,1733,1734] 70% 60% 50% 40% 30% 20% 10% 0% No invasive evaluation IVUS FFR My Hospital Comparison Group US Hospitals Stent Use: Average # of stents per PCI admission. [Detail Line:1793,1794] Number of Stents 1.4 1.2 1 0.8 0.6 0.4 0.2 0 All Stents DES My Hospital Comparison Group US Hospitals Outpatients: Proportion of PCI patient admissions whose hospital status was coded as "outpatient". [Detail Line:1390] NCDR